Tu1749 – Pharmacokinetics and Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Ulcerative Colitis: Results from the Unifi Induction Study
Omoniyi J. Adedokun(Western University), William J. Sandborn(University of San Diego), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Rupert W. Leong(The University of Sydney), Philippe Szapary, Tadakazu Hisamatsu(Kyorin University), Silvio Danese(IRCCS Ospedale San Raffaele), Colleen Marano(Johnson & Johnson (United States)), Zhenhua Xu(Beijing Institute of Education), Hongyan Zhang(Janssen (United States)), Christopher D. O’Brien(Cedars-Sinai Medical Center), Gert A. Van Assche, Jewel Johanns(Johnson & Johnson (United States)), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k